U.S. markets open in 3 hours 40 minutes
  • S&P Futures

    3,791.50
    -25.25 (-0.66%)
     
  • Dow Futures

    31,085.00
    -151.00 (-0.48%)
     
  • Nasdaq Futures

    12,578.75
    -103.00 (-0.81%)
     
  • Russell 2000 Futures

    2,182.70
    -23.10 (-1.05%)
     
  • Crude Oil

    60.84
    -0.44 (-0.72%)
     
  • Gold

    1,710.60
    -5.20 (-0.30%)
     
  • Silver

    25.93
    -0.46 (-1.73%)
     
  • EUR/USD

    1.2047
    -0.0020 (-0.17%)
     
  • 10-Yr Bond

    1.4700
    0.0000 (0.00%)
     
  • Vix

    27.44
    +3.34 (+13.86%)
     
  • GBP/USD

    1.3934
    -0.0019 (-0.13%)
     
  • USD/JPY

    107.3190
    +0.3170 (+0.30%)
     
  • BTC-USD

    49,305.98
    -1,996.50 (-3.89%)
     
  • CMC Crypto 200

    989.10
    +1.89 (+0.19%)
     
  • FTSE 100

    6,600.00
    -75.47 (-1.13%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

AcelRx Pharmaceuticals to Present at LD Micro Main Event

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

REDWOOD CITY, Calif., Dec. 9, 2020 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the use in medically supervised settings, today announced that management will be providing an overview of the business and company updates at the LD Micro Main Event to be held December 14 at 1:40 p.m. ET (10:40 a.m. PT). A live webcast link of the event can be found on the main conference website at https://ve.mysequire.com/.

For those not available to listen to the live webcast, a replay will be archived for 90 days and available through the conference website at https://ve.mysequire.com/.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO in Europe, indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and one product candidate, Zalviso®(sufentanil sublingual tablet system, SST system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings. DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S. For additional information about AcelRx, please visit www.acelrx.com.

AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.)
AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.) (PRNewsfoto/AcelRx Pharmaceuticals, Inc.)
Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-ld-micro-main-event-301189692.html

SOURCE AcelRx Pharmaceuticals, Inc.